Crestor vs Zetia: Titration Speed and Tolerability Compared

How Each Drug Actually Lowers LDL

Rosuvastatin and ezetimibe lower LDL through entirely different pathways, which is why combining them produces additive effects rather than redundant ones.

Rosuvastatin: HMG-CoA Reductase Inhibition

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis [1]. When hepatic cholesterol synthesis falls, LDL receptors on liver cell surfaces are upregulated, pulling more LDL out of circulation. At the maximum approved dose of 40 mg, rosuvastatin achieves 55 to 63% LDL reduction in clinical trials [2]. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol classifies rosuvastatin 20 to 40 mg as high-intensity therapy, defined as producing at least 50% LDL reduction [3].

Peak plasma concentration occurs at approximately 5 hours after oral dosing, and steady-state LDL reduction is measurable within 1 to 2 weeks, reaching a near-plateau by week 4 [2]. The prescribing label recommends reassessing lipids no sooner than 4 weeks after any dose change [4].

Ezetimibe: Intestinal Cholesterol Absorption Blockade

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestinal epithelium, reducing dietary and biliary cholesterol absorption by roughly 54% [5]. Because the liver compensates by upregulating LDL receptors, net LDL falls by 18 to 20% as monotherapy [6]. There is one dose: 10 mg once daily. No titration exists.

The important distinction is that ezetimibe's effect is additive to any statin because the two drugs block different steps in the same pathway. A 2016 meta-analysis in the Journal of the American College of Cardiology (N=27 trials, 22,311 patients) confirmed that adding ezetimibe to any statin background produced an additional 23.6% relative LDL reduction beyond statin alone [7].

Titration Speed: Rosuvastatin Takes Weeks, Ezetimibe Takes None

Titration speed differs sharply between these drugs, and that difference matters clinically when a patient needs rapid LDL lowering after an acute coronary event.

Rosuvastatin Titration Protocol

The standard starting dose for rosuvastatin is 10 to 20 mg daily for most adults, with 5 mg reserved for patients at higher myopathy risk (Asian ancestry, CYP2C9 metabolizer variants, or concomitant cyclosporine use) [4]. Per ACC/AHA 2018 guidance, clinicians reassess fasting lipids at 4 to 12 weeks after initiation, then at 3 to 12 month intervals once stable [3].

Dose escalation follows a doubling rule: 10 mg to 20 mg to 40 mg. Each step is separated by at least 4 weeks. The expected incremental LDL drop per doubling is approximately 6% (the "rule of 6s"), meaning most of rosuvastatin's total LDL-lowering power is already captured at the 10 mg or 20 mg dose [8].

Why Rapid Titration Carries Myopathy Risk

Dose-dependent myopathy limits how aggressively clinicians can up-titrate. The FDA label for rosuvastatin 40 mg notes that post-marketing surveillance identified higher rates of myopathy and rhabdomyolysis at 80 mg (not approved in the US), which is why 40 mg is the ceiling [4]. At approved doses, the absolute risk of clinically significant myopathy is low, roughly 1 per 10,000 patient-years for serious myopathy at 10 to 20 mg, rising with higher doses and drug interactions [9].

Ezetimibe: No Titration Required

Ezetimibe reaches steady-state plasma levels within 1 to 2 weeks and has no dose-response titration because 10 mg is the only available strength [5]. For a patient who needs additional LDL lowering without the 4-to-8-week wait for rosuvastatin up-titration, adding ezetimibe 10 mg produces a measurable LDL drop at the next lab check, typically within 4 weeks.

MACE Outcomes: What the Major Trials Show

Surrogate endpoints like LDL percentage reduction matter less than the question most patients actually ask: will this drug prevent a heart attack?

JUPITER Trial (Rosuvastatin)

JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) enrolled 17,802 apparently healthy adults with LDL <130 mg/dL but elevated high-sensitivity CRP (hsCRP >2 mg/L). Participants were randomized to rosuvastatin 20 mg or placebo. At a median follow-up of 1.9 years, rosuvastatin cut the primary MACE composite (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) by 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) [10]. LDL fell from a median of 108 mg/dL to 55 mg/dL, a 50% reduction.

The JUPITER investigators reported that rosuvastatin 20 mg reduced all-cause mortality by 20% (HR 0.80, 95% CI 0.67 to 0.97, P=0.02) [10]. That mortality signal in a primary prevention population remains one of the most cited arguments for high-intensity statin use.

IMPROVE-IT Trial (Ezetimibe Added to Simvastatin)

IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) enrolled 18,144 patients stabilized after acute coronary syndrome and randomized them to simvastatin 40 mg alone versus simvastatin 40 mg plus ezetimibe 10 mg. After a median follow-up of 6 years, the combination arm reduced the primary composite MACE endpoint by a relative 6.4% (HR 0.936, 95% CI 0.887 to 0.988, P=0.016) [11]. LDL in the combination group fell to a median of 53.7 mg/dL versus 69.5 mg/dL in the statin-only group.

IMPROVE-IT was the first randomized trial to show that adding a non-statin cholesterol-lowering agent to a statin produced incremental cardiovascular event reduction [11]. The trial's results are frequently cited in ACC/AHA Class IIa recommendations for adding ezetimibe when LDL remains above goal on maximally tolerated statin therapy [3].

Comparing the Two Trials Directly

These trials enrolled different populations (primary prevention in JUPITER versus post-ACS in IMPROVE-IT), used different comparators, and ran for different durations. Direct comparison is not appropriate. What is appropriate is noting that both drugs have Level A evidence for cardiovascular benefit, but via very different use-case logic: rosuvastatin as backbone high-intensity therapy, ezetimibe as a well-tolerated add-on when the LDL goal is not reached [3].

Tolerability: Side-Effect Profiles Side by Side

Tolerability is the practical reason most clinicians reach for ezetimibe as combination therapy rather than simply escalating rosuvastatin to 40 mg.

Rosuvastatin Tolerability Data

In a pooled analysis of 15 phase II and III trials (N=10,275), rosuvastatin at 5 to 40 mg produced treatment-emergent adverse events at rates similar to placebo, with muscle-related complaints in 3 to 5% of participants regardless of dose [2]. However, real-world data consistently show higher rates of patient-reported myalgia. The SAMSON trial (N=200, BMJ 2020) used a randomized crossover design and found that 90% of statin-attributed muscle symptoms occurred with equal frequency during placebo months, suggesting significant nocebo effects [12]. Still, genuinely statin-intolerant patients do exist, and up-titration to rosuvastatin 40 mg is not always feasible in practice.

New-onset diabetes is a recognized class effect. A meta-analysis published in The Lancet (N=91,140 across 13 trials) found statins increased diabetes risk by 9% overall, with higher-intensity regimens carrying modestly greater risk [13]. For rosuvastatin specifically, the JUPITER trial reported a diabetes incidence of 3.0% versus 2.4% for placebo over 1.9 years [10].

Ezetimibe Tolerability Data

Ezetimibe has a tolerability profile that is consistently close to placebo across trials. In IMPROVE-IT (N=18,144, median 6 years), discontinuation rates due to adverse events were 10.1% in the combination arm versus 9.9% in simvastatin alone, a non-significant difference [11]. Myopathy with ezetimibe monotherapy is rare; the FDA label reports muscle-related adverse events at rates below 2% in controlled trials [5].

Hepatic transaminase elevations (greater than three times the upper limit of normal) occurred in 0.5% of ezetimibe-monotherapy patients across phase III trials, compared to 0.1% for placebo [5]. This rate is lower than that typically observed with high-intensity statins.

Drug Interactions

Rosuvastatin is a substrate of OATP1B1 and BCRP transporters. Concomitant cyclosporine, gemfibrozil, or certain HIV protease inhibitors raise rosuvastatin plasma concentrations substantially and require dose capping at 5 mg or 10 mg [4]. Ezetimibe's interaction profile is narrower: fibrates may increase ezetimibe concentrations, and cyclosporine produces a bidirectional interaction, but neither interaction carries the myopathy escalation risk seen with statins [5].

When to Switch from Crestor to Zetia (and When Not To)

Switching rosuvastatin entirely to ezetimibe is rarely the right clinical choice. The two drugs are not interchangeable for LDL lowering because rosuvastatin 20 mg produces roughly 50% LDL reduction while ezetimibe 10 mg monotherapy produces only 18 to 20%. Switching from a high-intensity statin to ezetimibe monotherapy would leave most secondary-prevention patients well above guideline LDL targets.

Scenarios Where Switching Makes Sense

The ACC/AHA 2022 Expert Consensus Decision Pathway for Statin Intolerance defines statin intolerance as the inability to tolerate at least two statins, one at the lowest starting dose [14]. For a patient who has genuinely failed rosuvastatin 5 mg and an alternative statin (such as pravastatin 10 mg or fluvastatin 20 mg), ezetimibe 10 mg as monotherapy is a reasonable first-line non-statin option [14]. The patient will not achieve the same absolute LDL reduction, but they will achieve some LDL lowering with a drug they can actually take.

Scenarios Where Adding Ezetimibe Is Better Than Switching

For the larger group of patients on rosuvastatin who simply have not reached their LDL goal, adding ezetimibe 10 mg is strongly preferred over stopping rosuvastatin. The ACC/AHA 2018 guideline gives a Class IIa recommendation for ezetimibe addition when LDL remains above 70 mg/dL in very-high-risk patients despite maximally tolerated statin therapy [3]. Real-world pharmacy data suggest that only about 50% of very-high-risk patients achieve an LDL below 70 mg/dL on statin monotherapy, even with high-intensity regimens [15].

A Practical Titration Decision Framework

1. Start rosuvastatin 10 to 20 mg. Recheck lipids at 4 to 6 weeks.
2. If LDL is within 10 to 15% of goal, up-titrate rosuvastatin to 40 mg and recheck at 4 to 6 weeks.
3. If LDL remains above goal at rosuvastatin 40 mg, add ezetimibe 10 mg rather than exceeding the 40 mg ceiling.
4. If myalgia or CK elevation prompts a dose reduction, reduce rosuvastatin and add ezetimibe to maintain aggregate LDL lowering.
5. If the patient fails two statins at lowest doses per ACC/AHA 2022 criteria, transition to ezetimibe 10 mg monotherapy and consider PCSK9 inhibitor referral for secondary-prevention patients [14].

Dosing, Cost, and Generic Availability

Both rosuvastatin and ezetimibe are available as generics in the United States, substantially reducing the cost barrier that previously limited ezetimibe use.

Rosuvastatin Dosing

The FDA-approved dose range for rosuvastatin is 5 to 40 mg once daily taken at any time of day [4]. Unlike some other statins, rosuvastatin does not require evening administration because its half-life of approximately 19 hours allows consistent hepatic exposure regardless of dosing time [4].

Generic rosuvastatin became widely available after patent expiration in 2016. GoodRx pricing for 30 tablets of rosuvastatin 20 mg runs approximately $15 to 25 at most US pharmacies as of 2025, though prices vary by retailer and insurance formulary.

Ezetimibe Dosing

Ezetimibe 10 mg is the single available dose. It may be taken at any time of day, with or without food, and does not require dose adjustment for renal impairment or mild hepatic impairment [5]. Generic ezetimibe became available in 2017. The fixed-dose combination tablet (ezetimibe/simvastatin, brand name Vytorin) remains available but does not contain rosuvastatin.

No rosuvastatin/ezetimibe fixed-dose combination is FDA-approved in the US, though the combination is approved in other countries. US patients taking both drugs require two separate tablets.

Special Populations: Who Needs Extra Caution

Asian Patients and Rosuvastatin

The FDA label for rosuvastatin notes that Asian patients (Japanese, Chinese, Korean, Filipino, Vietnamese, Asian-Indian) show approximately two-fold higher rosuvastatin plasma AUC compared to white patients in pharmacokinetic studies [4]. The recommended starting dose in Asian patients is 5 mg, not 10 to 20 mg. This pharmacokinetic difference does not apply to ezetimibe [5].

Chronic Kidney Disease

Rosuvastatin dose should not exceed 10 mg daily in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) who are not on hemodialysis [4]. Ezetimibe requires no dose adjustment for any level of renal impairment [5]. For patients with CKD stage 4 or 5, ezetimibe is particularly useful for combination therapy because the statin dose ceiling lowers the achievable LDL reduction from rosuvastatin alone.

Pregnancy

Both rosuvastatin and ezetimibe are contraindicated in pregnancy [4][5]. The ACC/AHA 2018 guideline recommends discontinuing lipid-lowering therapy for women planning pregnancy, during pregnancy, and during lactation [3].

LDL Reduction: Numbers Side by Side

The table below summarizes expected LDL reductions based on prescribing data and major trial results.

| Regimen | Expected LDL Reduction | Evidence Source | |---|---|---| | Rosuvastatin 5 mg | ~38% | Prescribing information [4] | | Rosuvastatin 10 mg | ~43% | Prescribing information [4] | | Rosuvastatin 20 mg | ~48% | JUPITER trial [10] | | Rosuvastatin 40 mg | ~55 to 63% | Prescribing information [4] | | Ezetimibe 10 mg (mono) | ~18 to 20% | Prescribing information [5] | | Rosuvastatin 10 mg + Ezetimibe 10 mg | ~55 to 58% | Combined data estimate [7] | | Rosuvastatin 40 mg + Ezetimibe 10 mg | ~65 to 72% | Combined data estimate [7] |

The 2018 ACC/AHA guideline states: "For very-high-risk patients, a reasonable LDL-C goal is <70 mg/dL; if the LDL-C on maximally tolerated statin therapy remains >70 mg/dL, adding ezetimibe is reasonable." [3]

Safety Monitoring Recommendations

Baseline and Follow-Up Labs for Rosuvastatin

Per ACC/AHA guidance, a baseline fasting lipid panel, hepatic transaminases (ALT), and CK are reasonable before starting any statin [3]. Routine CK monitoring during stable therapy is not recommended unless the patient reports muscle symptoms [3]. Repeat fasting lipid panel at 4 to 12 weeks after initiation or dose change, then every 3 to 12 months once stable [3].

The FDA removed the routine monitoring of hepatic function from the rosuvastatin label in 2012, based on evidence that clinically meaningful hepatotoxicity from statins is rare and not reliably detected by periodic transaminase testing [16]. Liver function tests should still be obtained if symptoms of hepatic injury develop.

Safety Monitoring for Ezetimibe

The ezetimibe label recommends checking liver enzymes if ezetimibe is used with a statin, per the monitoring schedule for that statin [5]. No additional CK monitoring beyond statin protocol is required when ezetimibe is added to a statin.